Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment
Aim: Follow-up strategies for high-grade bone sarcomas have been optimized to facilitate early detection of local recurrence and distant metastasis. The ideology is that early detection enables early treatment presuming better survival. However, the clinical value for each individual patient remains...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-02-01
|
| Series: | Journal of Bone Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137422000562 |
| _version_ | 1811169483023187968 |
|---|---|
| author | Louren M. Goedhart Vincent K.Y. Ho Joris J.W. Ploegmakers Ingrid C.M. van der Geest Michiel A.J. van de Sande Jos A. Bramer Martin Stevens Paul C. Jutte |
| author_facet | Louren M. Goedhart Vincent K.Y. Ho Joris J.W. Ploegmakers Ingrid C.M. van der Geest Michiel A.J. van de Sande Jos A. Bramer Martin Stevens Paul C. Jutte |
| author_sort | Louren M. Goedhart |
| collection | DOAJ |
| description | Aim: Follow-up strategies for high-grade bone sarcomas have been optimized to facilitate early detection of local recurrence and distant metastasis. The ideology is that early detection enables early treatment presuming better survival. However, the clinical value for each individual patient remains questionable. This study aims to evaluate oncological events after initial treatment in order to assess current follow-up strategies for high-grade bone sarcomas in the Netherlands. Patients and Methods: A retrospective cohort study was conducted based on a national registry. All cases were retrieved from the Netherlands Cancer Registry. Our study consisted of 393 patients treated between 2007 and 2011 with complete follow-up data. Baseline characteristics were analysed for all entities. Local recurrence and distant metastasis was analysed along with overall survival for high-grade chondrosarcoma, high-grade osteosarcoma, Ewing sarcoma and chordoma. Results: Median follow-up was 8,3 years for high-grade chondrosarcoma, 4,9 for high-grade osteosarcoma, 3,8 for Ewing sarcoma and 7,5 for chordoma. Median time to local recurrence and distant metastasis was 1,2 years for high-grade osteosarcoma and 1,5 years for Ewing sarcoma. For high-grade osteosarcoma with localized disease at presentation, 0.09 new distant metastatic events per patient per year were seen after five years of follow-up with 11,1 patients needed to follow-up for any event. Five-year overall survival was 60,0% for high-grade chondrosarcoma, 50,0% for high-grade osteosarcoma, 45,3% for Ewing sarcoma and 71,4% for chordoma. Conclusions: This nationwide study shows a plateau in local recurrences and distant metastatic events after four years of treatment for patients with high-grade osteosarcoma and Ewing sarcoma. Due to a lack of reliable evidence however, we were not able to provide additional guidance on follow-up intervals and duration. Collaborative research with larger groups is needed in order to provide a solid scientific recommendation for follow-up in the heterogenous patient population with bone sarcoma. |
| first_indexed | 2024-04-10T16:43:10Z |
| format | Article |
| id | doaj.art-50c8b9eeab7f400cbf92021d5d3b6f4d |
| institution | Directory Open Access Journal |
| issn | 2212-1374 |
| language | English |
| last_indexed | 2024-04-10T16:43:10Z |
| publishDate | 2023-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Bone Oncology |
| spelling | doaj.art-50c8b9eeab7f400cbf92021d5d3b6f4d2023-02-08T04:16:48ZengElsevierJournal of Bone Oncology2212-13742023-02-0138100466Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatmentLouren M. Goedhart0Vincent K.Y. Ho1Joris J.W. Ploegmakers2Ingrid C.M. van der Geest3Michiel A.J. van de Sande4Jos A. Bramer5Martin Stevens6Paul C. Jutte7Department of Orthopaedics, University of Groningen, University Medical Center Groningen, The Netherlands; Corresponding author at: University Medical Center Groningen, Postbus 30.001, 9700 RB Groningen, The Netherlands.Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The NetherlandsDepartment of Orthopaedics, University of Groningen, University Medical Center Groningen, The NetherlandsDepartment of Orthopaedics, Radboud University Medical Center, Nijmegen, The NetherlandsDepartment of Orthopaedics, Leiden University Medical Center, The NetherlandsDepartment of Orthopaedics, Amsterdam University Medical Centers, Amsterdam, The NetherlandsDepartment of Orthopaedics, University of Groningen, University Medical Center Groningen, The NetherlandsDepartment of Orthopaedics, University of Groningen, University Medical Center Groningen, The NetherlandsAim: Follow-up strategies for high-grade bone sarcomas have been optimized to facilitate early detection of local recurrence and distant metastasis. The ideology is that early detection enables early treatment presuming better survival. However, the clinical value for each individual patient remains questionable. This study aims to evaluate oncological events after initial treatment in order to assess current follow-up strategies for high-grade bone sarcomas in the Netherlands. Patients and Methods: A retrospective cohort study was conducted based on a national registry. All cases were retrieved from the Netherlands Cancer Registry. Our study consisted of 393 patients treated between 2007 and 2011 with complete follow-up data. Baseline characteristics were analysed for all entities. Local recurrence and distant metastasis was analysed along with overall survival for high-grade chondrosarcoma, high-grade osteosarcoma, Ewing sarcoma and chordoma. Results: Median follow-up was 8,3 years for high-grade chondrosarcoma, 4,9 for high-grade osteosarcoma, 3,8 for Ewing sarcoma and 7,5 for chordoma. Median time to local recurrence and distant metastasis was 1,2 years for high-grade osteosarcoma and 1,5 years for Ewing sarcoma. For high-grade osteosarcoma with localized disease at presentation, 0.09 new distant metastatic events per patient per year were seen after five years of follow-up with 11,1 patients needed to follow-up for any event. Five-year overall survival was 60,0% for high-grade chondrosarcoma, 50,0% for high-grade osteosarcoma, 45,3% for Ewing sarcoma and 71,4% for chordoma. Conclusions: This nationwide study shows a plateau in local recurrences and distant metastatic events after four years of treatment for patients with high-grade osteosarcoma and Ewing sarcoma. Due to a lack of reliable evidence however, we were not able to provide additional guidance on follow-up intervals and duration. Collaborative research with larger groups is needed in order to provide a solid scientific recommendation for follow-up in the heterogenous patient population with bone sarcoma.http://www.sciencedirect.com/science/article/pii/S2212137422000562ChondrosarcomaOsteosarcomaEwing sarcomaFollow-up |
| spellingShingle | Louren M. Goedhart Vincent K.Y. Ho Joris J.W. Ploegmakers Ingrid C.M. van der Geest Michiel A.J. van de Sande Jos A. Bramer Martin Stevens Paul C. Jutte Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment Journal of Bone Oncology Chondrosarcoma Osteosarcoma Ewing sarcoma Follow-up |
| title | Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment |
| title_full | Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment |
| title_fullStr | Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment |
| title_full_unstemmed | Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment |
| title_short | Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment |
| title_sort | bone sarcoma follow up a nationwide analysis of oncological events after initial treatment |
| topic | Chondrosarcoma Osteosarcoma Ewing sarcoma Follow-up |
| url | http://www.sciencedirect.com/science/article/pii/S2212137422000562 |
| work_keys_str_mv | AT lourenmgoedhart bonesarcomafollowupanationwideanalysisofoncologicaleventsafterinitialtreatment AT vincentkyho bonesarcomafollowupanationwideanalysisofoncologicaleventsafterinitialtreatment AT jorisjwploegmakers bonesarcomafollowupanationwideanalysisofoncologicaleventsafterinitialtreatment AT ingridcmvandergeest bonesarcomafollowupanationwideanalysisofoncologicaleventsafterinitialtreatment AT michielajvandesande bonesarcomafollowupanationwideanalysisofoncologicaleventsafterinitialtreatment AT josabramer bonesarcomafollowupanationwideanalysisofoncologicaleventsafterinitialtreatment AT martinstevens bonesarcomafollowupanationwideanalysisofoncologicaleventsafterinitialtreatment AT paulcjutte bonesarcomafollowupanationwideanalysisofoncologicaleventsafterinitialtreatment |